Mixed kappa/mu opioids and uses thereof

Details Mixed kappa/mu opioids and uses thereof Mixed kappa/mu opioids and uses thereof

2007-09-18

2007-09-18

Desai, Rita (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S282000, C546S043000

Reexamination Certificate

active

10716100

ABSTRACT:
This invention features opioid compounds having activity at kappa and mu receptors, methods for preparing the mu/kappa opioids, and methods for the treatment of pain or a dopamine dysregulation disease, such as schizophrenia, attention deficit hyperactivity disorder (ADHD), attention deficit hyperactivity disorder (ADD), Parkinson's disease, hyperprolactinemia, depression, and addiction.

REFERENCES:
patent: 3853889 (1974-12-01), Monkovic et al.
patent: 3936462 (1976-02-01), Albertson
patent: 3959290 (1976-05-01), Monkovic et al.
patent: 4154932 (1979-05-01), Montzka et al.
patent: 4228285 (1980-10-01), Montzka et al.
patent: 4246413 (1981-01-01), Montzka et al.
patent: 4277605 (1981-07-01), Buyniski et al.
patent: 6166211 (2000-12-01), Cain et al.
patent: 2004/0045562 (2004-03-01), Sapala et al.
Albertson et al., “Benzomorphans. Structure of a Position Isomer,”J. Med. Chem., 21:471-474 (1978).
Archer et al., “Pentazocine. Strong Analgesics and Analgesic Antagonists in the Benzomorphan Series,”J. Med. Chem. 7:123-127 (1964).
Berke et al., “Addiction, Dopamine, and the Molecular Mechanisms of Memory,”Neuron25:515-532 (2000).
Bidlack et al., “8-Carboxamidocydazocine: A Long-Acting, Novel Benzomorphan,”J. Pharm. Exp. Ther. 302:374-380 (2002).
Fawzi et al., “SCH-202676: An Allosteric Modulator of Both Agonist and Antagonist Binding to G Protein-Coupled Receptors,”Mol. Pharm. 59:30-37 (2001).
Gutkowska et al., “The Synthesis and Pharmacological Activity of Two New Derivatives of Benzazocine,”Pol. J. Pharmacol. Pharm. 43:153-163 (1991).
Hayes et al., “A Series of Novel, Highly Potent and Selective Agonists for the κ-opioid Receptor,”Br. J. Pharmacol. 101:944-947 (1990).
Hayes and Birch, “Reversal by β-Funaltrexamine and 16-Methyl Cyprenorphine of the Antinociceptive Effects of Opioid Agonists in the Mouse and Guinea-Pig,”Neuropharmacology27:813-816 (1988).
Jordan et al., “Opioids and Their Complicated Receptor Complexes,”Neuropsychopharmacology23:S5-S18 (2000).
Kaczor and Matosiuk, “Non-peptide Opioid Recptor Ligands—Recent Advances. Part I—Agonists,”Curr. Med. Chem. 9:1567-1589 (2002).
Lambert et al., “Analgesics and Narcotic Antagonists in the Benzomorphan and 8-Oxamorphinan Series. 5.,”J. Med. Chem. 21:423-427 (1978).
Lemaire et al., “14-β-Methyl-8-Oxacyclorphan (BC-3016), a Morphinan Derivative with High Affinity for Kappa Opioid Receptor: Comparison with Dynorphin-A(1-13),” 64:707-711 (1986).
May and Eddy, “Interesting Pharmacological Properties of the Optical Isomers of α-5,9-Diethyl-2′-hydroxy-2-methyl-6,7-benzomorphan,”J. Med. Chem. 9:851-852 (1966).
McElroy et al., “Synthesis, Antinociceptive Activity, and Opioid Receptor Profiles of 10-Substituted-6-oxamorphinans,”J. Chem. Soc. Perkin Trans. 11563-1571 (1990).
McKenzie et al., “5-Aryl-3-azabicyclo[3.2.0]heptan-6-one Ketals, Compounds with Morphine-Like Analgesic Activity,”J. Med. Chem. 27:628-632 (1984).
John L. Neumeyer “Mixed Kappa-Mu Opioids: Synthesis and Evaluation” Abstract for NIH Grant No. 2R01DA014251-04A1, Sep. 1, 2001.
Szmuszkovicz, “U-50,488 and the κ Receptor Part II*: 1991-1998,”Progress in Drug Research53:1-51 (1999).
Ucar et al., “2 (3H) -Benzoxazolone and 2(3H)-Benzothiazolone Derivatives: Novel, Potent and Selective δ, Receptor Ligands,”Eur. J. Pharmacol. 355:267-273 (1997).
Wentland et al., “3-Carboxamido Analogues of Morphine and Naitrexone: Synthesis and Opioid Receptor Binding Properties,”Bioorg. Med. Chem. Lett. 11:1717-1721 (2001).
Wentland et al., “8-Carboxamidocyclazocine Analogues: Redifining the Structure-Activity Relationships of 2,6-Methano-3-benzazocines,”Bioorg.&Med. Chem. Lett. 11:623-626 (2001).
Wise, “Neurobiology of Addiction,”Curr. Opin. Neurobiol. 6:243-251 (1996).
Yokoyama et al., “Syntheses, Analgetic Activity, and Physical Dependence Capacity of 5-Phenyl-6,7-benzomorphan Derivatives,”J. Med. Chem. 22:537-553 (1979).
Zhang et al., “Synthesis of Aminothiazole Derived Morphinans,”Tetrahedron Lett. 44:6459-6462 (2003).
Zimmerman and Leander, “Opioid Antagonists: Structure Activity Relationships,”NIDA Res. Monogr. 96:50-60 (1990).

Affiliated with

Also associated with

Rating

Mixed kappa/mu opioids and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Mixed kappa/mu opioids and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mixed kappa/mu opioids and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3764849